Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1876 to 1890 of 8213 results

  1. TAK-880 for managing primary immunodeficiency diseases in people hypersensitive to IgA [TSID11883]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  2. Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease in people 12 to 17 years [TSID11887]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  3. Dapsone for treating COVID-19 in people 40 years and over with high-risk comorbidity and people 70 years and over [TSID11892]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  4. Subcutaneous ocrelizumab for treating primary progressive or relapsing multiple sclerosis [TSID11895]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  5. Subcutaneous C1-esterase inhibitor for preventing recurrent attacks of hereditary angioedema in people 12 years and over [TSID11891]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  6. Avtozma (tocilizumab biosimilar) for treating moderate to severe rheumatoid arthritis in people aged 18 to 75 [TSID11848]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  7. Melanoma (metastatic) - talimogene laherparepvec [ID508]

    In development Reference number: GID-TAG509 Expected publication date:  28 September 2016

    Technology appraisal guidance
    In development

  8. Natural Cycles for monitoring fertility

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  9. Ondansetron for treating alcohol-use disorder [ID6341]

    Awaiting development Reference number: GID-TA11375 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Lurbinectedin for treating advanced platinum-resistant ovarian cancer ID1340

    In development Reference number: GID-TA10313 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women ID1401

    In development Reference number: GID-TA10326 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Fingolimod for treating relapsing multiple sclerosis in children and young people [ID1378]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  13. Benralizumab for treating hypereosinophilic syndrome in people 12 years and over [ID6322]

    Awaiting development Reference number: GID-TA11360 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Alpelisib for treating severe PIK3CA-related overgrowth spectrum in people 2 years and over [ID6252]

    Awaiting development Reference number: GID-TA11284 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Sulthiame for treating self-limiting epilepsy with centrotemporal spikes in children TSID 12106

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation